Search

Your search keyword '"Mabro M"' showing total 143 results

Search Constraints

Start Over You searched for: Author "Mabro M" Remove constraint Author: "Mabro M"
143 results on '"Mabro M"'

Search Results

1. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

2. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)

3. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial

5. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings†

8. 1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

13. Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

17. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

19. Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results

21. Clinical characteristics of colorectal cancer patients with brain metastases: An "Association des Gastro-Éntérologues Oncologues" (AGEO) multicenter study

24. Bevacizumab-Erlotinib As Maintenance Therapy in Metastatic Colorectal Cancer. Final Results of the Gercor Dream Study

28. Geriatric parameters to predict chemotherapy feasibility in elderly patients (≥75 years) with advanced colorectal cancer: Preliminary results of a GERCOR-GEPOG cohort study.

33. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study

42. Toux et cancer du rein

47. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.

48. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.

49. A risk-benefit assessment of amifostine in cytoprotection.

Catalog

Books, media, physical & digital resources